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Levodopa medication is the most efficient treatment for motor symptoms of Parkinson’s 
disease (PD). Levodopa significantly alleviates rigidity, rest tremor, and bradykinesia in 
PD. The severity of motor symptoms can be graded with UPDRS-III scale. Levodopa 
challenge test is routinely used to assess patients’ eligibility to deep-brain stimulation 
(DBS) in PD. Feasible and objective measurements to assess motor symptoms of PD 
during levodopa challenge test would be helpful in unifying the treatment. Twelve patients 
with advanced PD who were candidates for DBS treatment were recruited to the study. 
Measurements were done in four phases before and after levodopa challenge test. Rest 
tremor and rigidity were evaluated using UPDRS-III score. Electromyographic (EMG) sig-
nals from biceps brachii and kinematic signals from forearm were recorded with wireless 
measurement setup. The patients performed two different tasks: arm isometric tension 
and arm passive flexion–extension. The electromyographic and the kinematic signals 
were analyzed with parametric, principal component, and spectrum-based approaches. 
The principal component approach for isometric tension EMG signals showed significant 
decline in characteristics related to PD during levodopa challenge test. The spectral 
approach on passive flexion–extension EMG signals showed a significant decrease
on involuntary muscle activity during the levodopa challenge test. Both effects were 
stronger during the levodopa challenge test compared to that of patients’ personal 
medication. There were no significant changes in the parametric approach for EMG and 
kinematic signals during the measurement. The results show that a wireless and wear-
able measurement and analysis can be used to study the effect of levodopa medication 
in advanced Parkinson’s disease.
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1. inTrODUcTiOn
Parkinson’s disease (PD) is a progressive neurodegenerative disease mainly among the old with 
increasing incidence with age (1, 2). There is no cure for PD. The main symptoms of PD are rigidity, 
rest tremor, bradykinesia, and postural instability (3). Majority of patients with PD experience rest 
tremor during their course of disease. Rest tremor can be present either in the beginning or a latter 
Table 1 | Patient demographic and medication data.
# sex age Dur. h and Y UPDrs-iii UPDrs-iii leDD Test
Med off Med off Med on Dose
1 F 48 11 3 25 3 1,250 150
2 M 46 5 2 33 11 700 150
3 F 47 14 3 0 0 1,600 150
4 F 63 8 3 37 14 935 150
5 M 56 9 3 43 16 1,175 300
6 M 60 9 3 33 17 1,030 200
7 M 44 7 2 43 18 1,030 300
8 F 62 14 3 30 8 520 75
9 M 55 8 3 37 10 1,695 300
10 M 52 6 4 55 20 1,780 400
11 M 58 10 3 38 9 1,355 250
12 M 62 11 2 35 14 1,153 200
Hoehn and Yahr stage was determined on range 1–5. UPDRS-III was determined with 
and without medication during the study. UPDRS-III is missing for the patient 3 due 
to interrupted measurement. The levodopa equivalent doses for medication of each 
patient has been calculated according to Ref. (39). The test dose was 50% higher than 
the patients’ normal medication dose.
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phase of the disease, or the whole time. Rigidity is characterized 
by increased resistance in the limbs. Along with rest tremor, rigid-
ity hinders activity of daily living (ADL) in PD. With appropriate 
treatment, it is possible to relieve the symptoms of the disease 
and thus improve ADL of PD patients to maintain their active 
life several years longer.
The symptoms of PD can be alleviated with multiple types of 
medication. Levodopa medication is currently the most efficient 
treatment for PD, and it alleviates the motor symptoms. COMT-
inhibitors are often used to enhance the duration of levodopa 
treatment effect. Mild symptoms of PD can be treated with a 
combination of other medication, such as dopamine agonists 
and MAO-B inhibitors, alone or in combination (4). This allows 
delaying of levodopa treatment, because duration and dose of 
levodopa treatment are associated with appearance of dyskinesia 
and motor fluctuations. Up to 50% of PD patients experience 
dyskinesia or motor fluctuations within 5 years from the onset of 
levodopa medication (4).
When motor symptoms can no longer be adequately controlled 
with medication, deep-brain stimulation (DBS) can be intro-
duced. Electrodes are implanted in either subthalamic nucleus 
(STN) or internal segment of globus pallidus (5, 6) for dyskinesia 
and motor symptoms or to ventral intermediate thalamic nucleus 
(VIM) (7) for tremor control, to give continuous electrical stimu-
lation via stimulation device. DBS has been shown to be more 
efficient than optimal medication to control motor fluctuations 
and dyskinesias, when the patient selection is done correctly (8). 
Levodopa challenge test is the most important single test to assess 
efficacy of DBS in advanced PD. Positive levodopa challenge test 
predicts successful outcome from DBS treatment (5, 9).
The symptoms of PD can be assessed by using Unified 
Parkinson’s Disease Rating Scale (UPDRS). UPDRS is a well-
established rating scale to assess the multitude of PD symptoms. 
The third part, UPDRS-III, is based on motor assessment (0–108 
points). Levodopa challenge test can be used to determine the 
effect of levodopa in patients with PD. The UPDRS-III score is 
determined before the dosage and approximately 30–60 min after 
the dosage of levodopa, when the medication effect is maximal. 
Over 30% decrease of UPDRS-III score in challenge test is gener-
ally regarded positive to introduce DBS in PD (5, 9).
Surface electromyographic (EMG) and kinematic methods 
have been established during last two decades for the clinical 
research of PD, and they can extract multitude features (10). It has 
been shown that the EMG signals of PD patients have different 
characteristics compared to healthy controls. The complexity of 
signals is reduced (11, 12), and more rhythmic bursts and pattern 
like behavior has been observed (13). Kinematic measurements 
are sensitive for tremor patterns. EMG and kinematic based 
analyses have been used to observe gait (14), REM sleep (15), 
medication response (13, 16–18), and DBS treatment (17, 19, 
20) in PD. During recent years, the measurement devices have 
become smaller, portable, and wireless. This has made the meas-
urements more feasible, thus longer and more measurements are 
available. Methods to classify parkinsonian symptoms during 
unconstrained activity have been presented (21–23). EMG and 
kinematic methods have been used to recognize levodopa-
induced dyskinesias during medication response (24–26).
Traditional methods for analyzing the EMG and the kinematic 
signals include amplitude and spectral-based measures. These 
methods allow for the determination of the strength of muscle 
activation, muscle conduction velocity, firing rate of motor 
units, and fatigue. The kinematic signals can be quantified with 
amplitude and power measures. There are newer techniques for 
analyzing the EMG and the kinematic signals that include linear 
and non-linear parametrizations as well as methods which are 
statistics related. These methods focus more on the morphology 
of the EMG signal than amplitude and frequency. The EMG and 
the kinematic signals in PD have been studied with amplitude 
and spectral based methods (15, 17, 27–31), wavelet-based 
approaches (32–34), linear and non-linear parameters (11, 20), 
EMG-burst shape analysis (13, 35, 36) and principal component 
approach (37, 38).
In this study, we measure and analyze EMG and kinematic 
signals during isometric arm tension task with linear and 
non-linear methods as they have been proven to be effective 
for analyzing signals from patients with PD (12). For analyzing 
EMG signals during passive flexion–extension of arm, we use 
spectrum-based methods since they are well established and 
robust enough to analyze non-stationary signals during arm 
movement. There are two purposes for the present study: to 
devise a method that consists of measurements and analysis to 
objectively assess the levodopa challenge test and to prove that a 
wearable and wireless measurement can be used for monitoring 
the treatment of PD.
2. MaTerials anD MeThODs
2.1. subjects
After a written informed consent, EMG and kinematic signals 
of 12 (8 males, 4 females) patients with advanced PD were 
measured (Table  1). The UPDRS-III score was determined 
during the measurement to estimate the benefit of DBS for the 
patient. The patients had DBS later if they met all the selection 
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criteria. The study was approved by human ethics committee 
of the Kuopio University Hospital. The age of the patients was 
(58 ± 7) (mean ± SD) years and they had had the PD diagnosis 
(9 ± 3) years before the measurement. The UPDRS-III score for 
the patients was (37 ± 8) before the administration and (13 ± 5) 
after 60 min of administration of levodopa.
All measurements were done in the morning when the patients 
had been about 10–12  h without antiparkinsonian medication. 
The patients did neither have breakfast nor coffee before the meas-
urement. UPDRS-III score was determined by an experienced 
neurologist. The rigidity and rest tremor assessments during the 
measurements were conducted by the measurement person.
All parts of the measurements were done while the patient was 
sitting upright, with their feet on the ground, on a wooden stool 
which had no armrests. The condition of patients was adequate 
when taking into account the UPDRS-III score and thus all of 
them were able to sit throughout the measurement. The patients 
were let to rest on their hospital bed between the measurement 
phases if needed.
2.2. Measurement Protocol
EMG and kinematic measurements were used to observe effects 
of levodopa during the levodopa challenge test. Before attaching 
the EMG electrodes, the surface of the skin beneath was properly 
cleaned with ethanol wetted cotton pads. Disposable Ag/AgCl 
surface electrodes (Medicotest M-00-S) were placed on top of 
left and right biceps brachii muscle, below the belly of the muscle 
with interelectrode distance 3  cm. The reference electrode was 
placed to an inactive point on the lateral side of brachium, 6–7 cm 
from the recording electrodes. The whole measurement was 
done without detaching the electrodes in between. For record-
ing arm kinematics, triaxial accelerometers (MEAC-X, ±10  g 
Mega Electronics) were attached to anterior side of forearm, 
halfway between the wrist and the elbow of both arms, to record 
the movement of arms during the measurement. The signals 
were recorded with wireless ME6000 biosignal monitor (Mega 
Electronics Ltd., Kuopio, Finland) with sampling rate 1,000 Hz. 
The resolution was 1 µV for EMG acquisition and 2 milligravity 
for acceleration acquisition. The wireless measurement provides 
a shield from unwanted noise in the signals.
The measurement took place four times in total: before 
levodopa dose (phase I), 30 min after levodopa dose (phase II), 
60 min after levodopa dose (phase III). After the levodopa chal-
lenge test was over, the patient was guided how to return into his 
daily medication rhythm depending on the medication response 
he was having. One more measurement (phase IV) was done 
60 min after the patient had taken his personal medication dose.
2.2.1. Task 1: Isometric Elbow Flexion
The patient was asked to hold his elbows in 90° angle with palms 
facing upwards. The elbows were not allowed to be supported by 
body sides. The patient held arms in this position for 30 s and was 
advised to not restrict possibly emerging tremor during the task.
2.2.2. Task 2: Passive Elbow Flexion–Extension
The patient was asked to relax his arms on top of his feet. Then 
the patients’ elbow joint was flexed and extended periodically by 
holding other hand on the elbow joint and another on patients 
hand to allow natural track of movement. The patient was advised 
to not act or counteract with the movement. The measurement 
started after the patient relaxed his arm completely and did not 
perform any voluntary movements. The flexion–extension move-
ment was repeated 9–10 times for each arm separately.
2.3. analysis
The tasks were segmented from the measurement and the signals 
checked for artifacts and inconsistencies. The measurement of 
one patient was interrupted by other treatment and could not be 
proceeded along the protocol. The patient was omitted from the 
analysis.
The EMG and the kinematic signals were preprocessed for 
the analysis by removing possible baseline drift with smoothness 
priors method (40). The method resembled a high pass filter with 
cut off frequency 10 Hz for the EMG and 2 Hz for the kinematic 
signals. Then the EMG and kinematic signals were divided to 
short epochs of 1,024 ms with overlap 768 ms for isometric elbow 
flexion and 512 ms with overlap 384 ms for passive flexion–exten-
sion measurement. In the following analyses, the parameters and 
the histograms are first calculated for the epochs separately and 
then averaged over the epochs.
2.3.1. Task 1: Isometric Elbow Flexion
Parameters characterizing EMG and kinematic signals were 
calculated for the signals measured during the isometric elbow 
flexion. The parameters were calculated in similarly to Ref. (11, 
12). EMG shape characterizing parameters kurtosis (KURT), 
SD, root mean-square value (RMS), median frequency (MDF), 
sample entropy (SampEn), correlation dimension (D2), deter-
minism (DET), and recurrence of bursts (REC) were determined 
for EMG signals. Further, parameters characterizing kinematic 
signals, root mean-square value (ARMS), sample entropy 
(ASampEn), and cross sample entropy (CSampEn), were deter-
mined. The group mean and SD over patients were calculated 
for each phase.
The analysis was expanded by calculating 50 bin sample his-
tograms for the EMG signals. Then the left and right side EMG 
histogram were concatenated for each patient and each measure-
ment resulting four histogram-vectors for each patient, a total of 
11 × 4 vectors.
These vectors are used as the feature vectors of principal com-
ponent approach. In this analysis, the directions in which the data 
has the greatest variance are determined.
The feature vectors zj can be modeled with linear model,
 z H vj j j= + ,θ  (1)
where H is the model matrix containing the basis vectors ϕ1 … ϕk 
as columns. The basis vectors are the directions in which the data 
has the greatest variance. The parameter θj contains the principal 
components. The parameter Vj contains the model error. Each 
feature vector can be expressed as a linear combination of basis 
vectors multiplied by principal components
 z K vj j j K j j= + + + + .φ θ φ θ φ θ1 21 2( ) ( ) ( )  (2)
Table 2 | UPDRS-III score and limb rest tremor and rigidity during the 
measurement phases I–IV.
UPDrs-iii Tremor rigidity
range 0–108 0–16 0–16
I 37.2 ± 7.9 1.9 ± 2.4 6.9 ± 3.2
II – 0.4 ± 0.5 3.0 ± 3.2
III 12.7 ± 5.0 0.0 ± 0.0 2.0 ± 2.5
IV – 0.5 ± 1.2 3.5 ± 2.4
The whole UPDRS-III was done in phases I and III, the limb rigidity and rest tremor 
assessment were done in each phase I–IV. The maximum of each item in UPDRS-III is 4, 
though the whole range of limb tremor and rigidity is 0–16.
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The linear model can be presented in matrix form if the data 
set consists of multiple measurements or patients. In this work, 
feature matrix Z is formed from feature vectors of every subject 
and every measurement (11 × 4 feature vectors). Now a corre-
sponding linear model can be written
 Z H v= + ,θ  (3)
where θ is the matrix of principal components and v the matrix 
of errors. The basis vectors were selected so that they are the 
eigenvectors of experimental correlation matrix
 
R
M
z z
M
ZZjM j jT T= = .=
1 1
1Σ  
(4)
With this selection, the first basis vector ϕ1 is the best mean-
square fit for the data set Z, the vector ϕ2 is the best mean-square 
fit for the residual of the first fit and further. Four basis vectors 
ϕ1 ∙ ϕ4 (BV1–BV4 from this on) of largest principal components 
were chosen to represent the original feature vectors. The prin-
cipal components can be solved from the linear model in the 
least-squares sense
 ˘ ( )θ = = .−H H H Z IH ZT T T1  (5)
Since the eigenvectors of R are orthonormal, HTH is a unit 
matrix.
2.3.2. Task 2: Passive Elbow Flexion–Extension
The EMG signals during passive elbow flexion–extension were 
analyzed with time dependent spectrum approach. The epoch 
length was 512  ms with 386  ms overlap. Short time Fourier 
transform was calculated for the epochs with the spectrogram 
function of MATLAB (MathWorks, USA). The frequency range 
was set between 0 and 200 Hz, since the spectral power above 
200 Hz was non-significant. The spectrum was observed visually 
and quantified by calculating mean power spectral density for 
each measurement. The values for the phases II, III, and IV were 
normalized with each patients phase I value to make the values 
comparable to other patients.
2.3.3. Statistical Tests
All statistical tests were performed so that the phases of each 
patient were compared to the phase I. Wilcoxon signed rank 
test was used to determine the significance of changes in the 
principal components, the spectrum means and the EMG and 
the kinematic parameters.
3. resUlTs
3.1. UPDrs-iii
During the levodopa challenge test, UPDRS-III score of the 
patients changed from (37 ±  8) to (13 ±  5) indicating signifi-
cant improvement of motor symptoms (Table 2). The decrease 
ranged from 48 to 88% in individuals and is considered a positive 
outcome for DBS installation. Rigidity was the most common 
symptom among the patients, but a majority showed also rest 
tremor. The Table  3 shows the group mean of the upper limb 
rigidity and rest tremor which were graded with UPDRS-III scale. 
Before the levodopa administration (phase I) the rigidity differed 
only slightly between the left and the right hand whereas the rest 
tremor seemed to be stronger on the right side. The rigidity and 
the rest tremor decreased already 30 min after the administration 
of levodopa (phase II). The effect became stronger and alleviated 
the rest tremor totally in the phase III, also the rigidity continued 
to decrease. In the last phase, the rigidity and the rest tremor 
began to increase indicating that the levodopa dosage given in 
levodopa challenge relieves the motor symptoms of the disease 
more than the patients’ personal medication.
3.2. Task 1: isometric elbow Flexion
The EMG and the kinematic signals for a single patient are shown 
in Figure S1 in Supplementary Material. There were some differ-
ences in the EMG signals between the different phases. In the 
phase I, the left hand EMG contained bursts which decreased in 
the phases II–IV. On the right hand side, the signal amplitude 
increased from the phase I to the phase III. The kinematic signals 
showed slightly less changes between the phases I–IV. The ampli-
tude was greatest in the phase II, but the frequency was slightly 
high (around 9 Hz) compared to typical Parkinsonian rest tremor 
(4–6 Hz).
The calculated EMG and kinematic parameters (Table  3) 
differed slightly between the phases. However, the deviation was 
high and there were no statistically significant changes either in 
the EMG or the kinematic parameters. According to the UPDRS-
III score, majority of the patients suffered from rest tremor. 
Traditionally this is easily picked up by kinematic measurement. 
However, in this study, the kinematic measurement and the signal 
RMS values showed that rest tremor is generally very low.
The characterization of the EMG signals was taken further 
by including principal component analysis. The basis vectors for 
characterization of the histograms are presented in Figure S2 in 
Supplementary Material. The first and the second BV character-
ized the histogram height and width, which are closely related to 
the EMG signal characteristics in PD. The third BV characterized 
the side differences in histogram peak height, whereas the fourth 
BV was a mixture of peak width and side differences. The principal 
components which showed the greatest difference between the 
phases, PC1 and PC2, are shown in Figure S3 in Supplementary 
Material. These two principal components are related to the 
signal burstiness. It is seen that in the phase II there are varying 
responses between the patients. While the PC1 decreases and the 
PC2 increases for most patients, opposite paths are observed also. 
Table 3 | Parameters of isometric tension task.
i ii iii iV
left right left right left right left right
UPDrs-iii of upper limb
Rigidity 2.00 ± 1.34 1.82 ± 0.98 1.00 ± 1.34 0.64 ± 1.03** 0.45 ± 0.93** 0.27 ± 0.90** 1.27 ± 1.56* 0.82 ± 0.60*
Tremor 0.50 ± 0.67 1.08 ± 1.31 0.08 ± 0.29 0.33 ± 0.65 0.00 ± 0.00 0.00 ± 0.00 0.25 ± 0.45 0.25 ± 0.62
eMg-parameters
KURT 4.79 ± 1.66 4.33 ± 0.65 4.42 ± 0.60 4.20 ± 0.66 4.49 ± 0.71 4.18 ± 0.55 4.34 ± 0.68 4.14 ± 0.49
DEV 0.34 ± 0.03 0.35 ± 0.03 0.34 ± 0.02 0.35 ± 0.02 0.34 ± 0.02 0.35 ± 0.03 0.35 ± 0.03 0.36 ± 0.02
RMS 46.8 ± 27.8 36.9 ± 10.1 65.1 ± 55.9 69.2 ± 75.7 67.7 ± 34.0 70.2 ± 58.5 49.4 ± 20.0 64.0 ± 37.9
MDF 71.0 ± 18.5 66.2 ± 14.8 67.3 ± 11.0 67.4 ± 15.3 66.0 ± 12.7 68.4 ± 13.5 69.0 ± 16.8 67.6 ± 16.9
REC 8.2 ± 3.5 8.9 ± 5.3 7.5 ± 2.9 9.0 ± 7.2 8.0 ± 3.0 6.9 ± 2.8 8.0 ± 2.9 8.6 ± 5.3
DET 9.7 ± 6.2 15.3 ± 15.6 9.7 ± 4.2 15.3 ± 15.8 11.9 ± 9.1 10.6 ± 9.4 10.5 ± 5.1 14.7 ± 14.1
SampEn 1.11 ± 0.26 1.16 ± 0.24 1.15 ± 0.13 1.17 ± 0.26 1.11 ± 0.22 1.20 ± 0.20 1.15 ± 0.19 1.18 ± 0.21
D2 6.23 ± 0.83 6.21 ± 1.03 6.40 ± 0.48 6.23 ± 1.30 6.26 ± 0.64 6.55 ± 0.69 6.26 ± 0.53 6.28 ± 1.11
Kinematic parameters
ARMS 0.06 ± 0.02 0.08 ± 0.09 0.06 ± 0.03 0.09 ± 0.11 0.08 ± 0.05 0.06 ± 0.04 0.09 ± 0.08 0.10 ± 0.08
ASampEn 1.14 ± 0.28 1.00 ± 0.37 1.11 ± 0.30 1.02 ± 0.36 1.11 ± 0.44 1.10 ± 0.26 0.97 ± 0.47 0.86 ± 0.37
CSampEn 1.28 ± 0.21 1.20 ± 0.32 1.25 ± 0.21 1.22 ± 0.26 1.26 ± 0.31 1.28 ± 0.14 1.23 ± 0.24 1.16 ± 0.20
Pca of eMg
PC1 0.50 ± 0.26 0.29 ± 0.20 0.22 ± 0.13* 0.32 ± 0.22**
PC2 0.65 ± 0.30 0.85 ± 0.15 0.91 ± 0.08* 0.80 ± 0.19**
PC3 0.39 ± 0.28 0.32 ± 0.18 0.25 ± 0.21 0.35 ± 0.33
PC4 0.62 ± 0.27 0.62 ± 0.15 0.58 ± 0.11 0.62 ± 0.14
UPDRS-III score for arm rigidity and rest tremor decreased in the phases I–III and increased in the phase IV compared to phase III. There were only slight changes in EMG and 
kinematic parameters between the phases, none of which was significant. The principal component approach showed significant difference between the phases I and III and 
between the phases I and IV. Values presented in format (mean ± SD). Significant change to first measurement *p < 0.05, **p < 0.01.
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In the phase III, the effect of medication is more homogeneous, 
nearly all of the patients experience decrease in the PC1 and 
increase in the PC2. In the phase IV, the response is similar to the 
phase III, but milder. Means and SDs of the coefficients PC1–PC4 
are shown in Table 3. For the PC1 and the PC2, it indicates the 
same results than the Figure S2 in Supplementary Material. It is 
seen that the PC3 changes similarly than the PC1, indicating that 
there is a decrease in side difference, but not significant. There was 
practically no change in the PC4 between the phases.
3.3. Task 2: Passive extension–Flexion 
Task
The time dependent spectrum of EMG activation during the pas-
sive flexion–extension task showed muscle activity even though 
the patients were not voluntarily tensing their muscles. The 
involuntary muscle activity was strongest in the phase I, while 
a decreasing trend was observed toward phases II and III. In the 
phase IV, a slight increase in activity compared to phase III is 
observed. Muscle activation in phases I and III for both hands of 
each patient is shown in Figure S4 in Supplementary Material. The 
decrease in involuntary activity is clear in most of the patients. We 
hypothesize that this is an indication of Parkinsonian rigidity. The 
EMG amplitudes are not directly comparable between the patients. 
However, the amplitudes can be compared between the measure-
ment phases of one patient, since all the phases were measured in 
the same session without moving or detaching the electrodes in 
between. The normalized mean power spectral density decreased 
to (0.88 ± 0.40, 0.63 ± 0.31**) (left, right) in the phase II (not 
shown in the figure), to (0.62 ± 0.39*, 0.51 ± 0.21**) in the phase 
III and increased again to (0.65 ±  0.40*, 0.68 ±  0.28**) in the 
phase IV (not shown in the figure). The change was significant 
compared to the phase I in the phases III and IV on the left arm, 
and in the phases II-IV on the right arm. Significances **p < 0.01, 
*p < 0.05.
4. DiscUssiOn
In this study, 12 patients with advanced PD went through tests 
to determine their applicability for DBS treatment. During the 
levodopa challenge test, the muscle activity and arm movements 
of the patients were measured, and 11 of them were analyzed. The 
results of the study proved that a wireless and wearable device 
combined with the presented analysis can be used to objectively 
monitor the muscle activity during levodopa challenge test.
The main finding of the study is that levodopa challenge test 
changes the characteristics of EMG and kinematic signals in 
patients with advanced PD. The proposed principal component 
approach suggests that the morphology of EMG changes due 
to levodopa administration so that the EMG histogram peak 
lowers and widens. The clinical indication of this is the alle-
viation of PD symptoms. Variation in the phase II suggests that 
the begin of medication response varies between the patients. 
The third PC shows slight decline in side difference, but the 
change was non significant. PD typically begins unilaterally 
and these results suggest that even though medication relieves 
the symptoms bilaterally, it failed to lessen the side difference 
between the left and the right arm. The nearly absent change 
in PC4 indicates that most of the differences in histograms are 
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described already by the three first PC’s and it is only used to 
fine tuning the histogram shape. The strength of the principal 
component approach is in the core of the method. It relies on 
determining the directions of data variation in the data set and 
thus is tailored to find the differences in that particular data set. 
This is a slight shortcoming of the method at the same time. The 
method needs a training set and it cannot be used for a single 
measurement.
The second main finding is that the effect of levodopa can 
be seen also in passive flexion–extension task. It was found that 
levodopa dosage decreases involuntary muscle tone in patients 
of PD. The results follow trend that is similar to the isometric 
task. In the phase II, there is more variation in the results, but 
in the phase III there is a clear decrease in involuntary muscle 
activation. In the phase IV, it is slightly increased compared 
to III, but still closer to phase III than phase I. Similar results 
for measurement during DBS treatment has been observed by 
Levin et al. (30). When comparing the UPDRS-III limb rigidity, 
similar trend is observed. We hypothesize that the decrease in 
rigidity is a result from decreased involuntary muscle activity. 
Thus, the passive flexion–extension measurement is connected 
to the Parkinsonian rigidity, and can be used to measure it. We 
are aware of the difficulties which this method poses: (1) the rate 
of limb flexion–extension was not controlled precisely and (2) 
the patients’ voluntary movement cannot be perfectly ruled out. 
The (1) can affect to power spectral density, but we assume that 
the effect is not significant since the measurement person used 
same speed for each patient (slightly less than 1/s). Also it can be 
speculated, that while rigidity could decrease the rate of move-
ment, which would also decrease the difference between phase 
I and phase III. The (2) can cause false (voluntary) movements 
during passive flexion–extension cycle. However, the patients 
were advised to keep their hand in rest while the movement 
and the measurement was not began before the measurement 
person felt the patient was not voluntarily contracting their 
muscles. While it can be argued that patients learn to relax their 
hand throughout the measurement, this is not the case accord-
ing to the data: during the fourth phase, most of the patients 
experienced increased rigidity which is also picked up by EMG 
measurement.
The third main finding was that unlike in earlier studies, the 
Parkinsonian symptoms were not visible in the parameters calcu-
lated from EMG and kinematic signals during the isometric task. 
Even patients who presented rest tremor during the UPDRS-III 
assessment, did not show significant tremor in the kinematic sig-
nals. This is an atypical finding since rest tremor is easily picked 
up by kinematic sensors. Multiple factors can affect to this. It is 
possible that patients (despite the advice) were restricting their 
tremor during the isometric measurement. This is quite common 
along the patients in general. The tremor in PD is mainly rest 
tremor which disappears during posture or kinetic tasks. It is pos-
sible that the isometric tension measurement measures postural 
tremor and, therefore, is not compatible method to measure rest 
tremor. However, contrary results have been observed in earlier 
studies (12, 38). In the third and fourth measurement, rest tremor 
is absent due to the medication. The patients in this study were 
going through a series of clinical trials which tell us if the patients 
would benefit from DBS treatment. Patients older than 70 years 
may tolerate DBS less well than younger patients like in this study. 
This affects to our patient selection, and it could be possible that 
previously mentioned issues are emphasized compared to general 
population of PD patients. This notion is backed up with the fact 
that the EMG signals show similar values for parameters for 
healthy controls as in our earlier study, even when the patients 
were off-medication. However, principal component approach is 
more capable to extract information from the EMG signals. In 
this approach, we see clear changes between the signals during 
the medication dosage. However, the number of subjects is small 
for drawing definitive statistical conclusions.
The results of the study indicate that the patients’ response to 
levodopa during levodopa challenge is stronger than the response 
to their own personal medication. This was an expected result: 
since the levodopa dosage in levodopa challenge test is 1.5 times 
the patients’ optimal dose, the response is also pronounced. 
However, this does not imply that the patients’ medication dos-
age is not optimal. When determining suitable medication dose, 
also the adverse effects have to be taken into account. During 
this measurement, part of the patients experienced levodopa-
induced dyskinesias and some of them were struggling to keep 
steady during the end of the phase III measurement due to strong 
medication response.
The strengths of this analysis are the feasible measurements, 
only the wireless measurement device is needed, as comparison 
to other methods which typically incorporate special equip-
ment such as manipulators to carry out the measurement. Even 
though the measurements are currently done with a wireless 
measurement device which is the size of a scientific calculator, 
the technology today allows this method to be directly used on 
even smaller devices. The analysis methods are not computer 
intensive which enables their use in simpler devices, for example 
the measurement device. Present method appears to objectively 
assess the effect of levodopa challenge test on muscle activity 
and activation patterns in advanced PD. However, there is no 
restriction for using the method to follow the effects of levodopa 
during the course of disease. With further research, this method 
can possibly be used also for analysis of long-time registration of 
medication response in PD.
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FigUre s1 | Three second segment of EMG and kinematic signals during 
isometric tension of left and right arm in one patient. EMG bursts decrease in 
phases I–III on left side, whereas EMG amplitude increases in phases I–IV on 
right side. There is more tremor-like activity in kinematic signals of phase II than 
others.
FigUre s2 | Basis vectors BV1–BV4 of the data set determined by PCA. BV1 
denotes EMG histogram peak height, BV2 peak width, BV3 the side differences, 
and BV4 is a partial mixture of side differences and peak height.
FigUre s3 | Principal components PC1 and PC2 in phases II–IV, normalized to 
the phase I. The phase II and the phase III show similar features. The phase IV 
indicates that the effect of the patients own medication is milder than that of the 
levodopa test dose (phase III). The phase I for each patient is marked with a solid 
circle while the hollow circles indicate the change from the phase I.
FigUre s4 | Left and right arm EMG spectral power during passive extension–
flexion task in phases I and III for each patient. White colour denotes higher 
spectral intensity. The EMG spectral power decreases from the phase I to the 
phase III in passive extension–flexion task.
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